Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | RRM1 | P23921 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27142716 | 0.83 | ACHE (0.40) | CASP2FAAHNAAAEPHX1MEN1 | |
| SCHEMBL25850206 | 0.82 | FAAH (0.43) | CASP2FAAHSLC6A5 | |
| SCHEMBL21569930 | 0.81 | KDM4E (0.32) | — | |
| SCHEMBL27109575 | 0.79 | CASP2 (0.41) | CASP2FAAHNAAAEPHX1SLC6A5 | |
| SCHEMBL26034080 | 0.75 | FAAH (0.47) | CASP2FAAHSLC6A5MEN1KMT2A | |
| SCHEMBL25840004 | 0.75 | KDM4E (0.33) | — | |
| SCHEMBL20417363 | 0.74 | CASP2 (0.56) | CASP2FAAHNAAAEPHX1MEN1 | |
| SCHEMBL25082495 | 0.74 | KMT2A (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL22942128 | 0.74 | KDM4E (0.33) | — | |
| SCHEMBL20121987 | 0.73 | CASP2 (0.59) | CASP2FAAHNAAAEPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CASP2 4430/4885FAAH 2901/4885NAAA 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.